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Introduction 
Colorectal cancer is the second most common cause of 
cancer-related death in both sex (1). Approximately 20% of 
the patients with colorectal cancer present with metastasis at 
the initial diagnosis, and up to 60% will develop metastasis 
during the course of disease. The liver plays a crucial role 
in the natural history of the disease as being the most 
common site of metastases, with progression of colorectal 
liver metastases (CLM) accounting for the main cause of 
mortality in 53% of the patients (2). Surgical eradication of 
the CLM is linked with improved overall survival (OS) rates 
and is warranted (3). Unfortunately, only 20–30% of the 
patients with CLM are resectable (4). 
Ablation is a well-established local therapy for patients 
with limited CLM extension. In such population subset, 
the combination of ablation with systemic chemotherapy 
has demonstrated improved OS when compared to 
systemic chemotherapy alone, as showed by the latest 
results of the CLOCC trial (5). Accordingly, the last 
version of the European Society for Medical Oncology 
Consensus guidelines (6) acknowledges for the first time 
the role of ablation for patients with CLM presenting 
with oligometastatic disease (OMD). Moreover, ongoing 
trials are currently investigating the use of ablation as a 
first approach for the treatment of CLM (7). To correctly 
select patients for ablation, it is of paramount importance to 
identify the factors that affect its outcomes.
Rat sarcoma viral oncogene (RAS) mutational status is a 
key factor for the clinical management of colorectal cancer 
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patients (8). Specifically, RAS mutation is a downstream 
component of the epidermal growth factor receptor (EGFR) 
signaling network, and it has been associated with resistance 
to medical treatments with EGFR antibodies. Furthermore, 
RAS mutation has been associated with higher incidence of 
disease recurrence and shorter OS following resection for 
CLM (9). Similarly, recent findings in the interventional 
radiology literature suggest interactions between RAS 
mutational status and image-guided ablation outcomes (10). 
Therefore, in this review, we aim to discuss the current 
literature on the influence of RAS mutational status on 
ablation outcomes, as well to provide a perspective on the 
future research on the impact of tumor molecular biology 
on liver ablation procedures.
Percutaneous image-guided ablation
Percutaneous image-guided ablation is routinely used as a 
safe and effective loco-regional therapy for the treatment 
of patients with CLM. Among the imaging modalities, 
computed tomography, ultrasound, and magnetic resonance 
imaging are the most commonly utilized. Its minimally 
invasive nature has several advantages: it can be easily 
repeated to treat progression; it does not impact surgical 
eligibility for those that can be eventually resected; it does 
not require prolonged chemotherapy interruption; and 
finally, it has minimal or no impact on patients' quality of 
life (11). Such facts are particularly important in view of the 
recurrent nature of CLM, which brings a high likelihood 
of requiring repeated local treatments even after successful 
resection or ablation.
From the early reports on the use of image-guided 
ablation for the treatment of patients with CLM in the 
late 90s (12) to the present time, technical developments 
and a deeper understanding of the oncologic mechanisms 
have led to improved therapeutic strategies and increased 
survival rates. During the last three decades, several 
ablative technologies have been proposed and reported 
in the literature: radiofrequency (RF), laser, cryoablation, 
microwave (MW), and irreversible electroporation (IRE). 
The two most used technologies are by far radiofrequency 
ablation (RFA) and, more recently, microwave ablation 
(MWA). 
RF systems induce coagulative necrosis resulting from 
thermal energy delivered by an alternating electrical current 
through the needle probe placed within the target tumor. 
An electrical circuit is completed through grounding pads, 
normally attached to the thighs. Temperatures range between 
60 to 100 ℃, resulting in coagulation necrosis. The major 
portion of the final ablation zone is due to thermal conduction 
into more peripheral areas around the electrode (13). 
MWA uses electromagnetic waves between 900 and 
2.4 GHz through the MW probe, which is called the 
antenna. These high-frequency electromagnetic waves cause 
oscillation and friction of water molecules with subsequent 
heat, resulting in tissue destruction by coagulation necrosis. 
MWA presents some theoretical advantages over RFA, 
such as reduced ‘heat-sink’ effect (lower heat dissipation in 
a vessel’s proximity) and larger ablation zones in a reduced 
period of time. For these reasons, MWA is thought to be 
more efficient in the treatment of larger lesions and for 
targets located near large vessels when compared to other 
thermal ablation modalities. However, presently, there is no 
clear evidence in favor of one technology over the other in 
the CLM ablation setting.
Factors affecting ablation outcomes
Local control of the ablated tumor is the main goal for an 
effective image-guided ablation. Presence of residual disease 
or development of tumor recurrence at the ablation zone 
is considered a treatment failure that the interventional 
radiologists should prevent. In the ablation literature, local 
recurrence is termed as “local tumor progression” (LTP), 
which is defined as the appearance of tumor foci at the edge 
of the ablation zone or within 1 cm from it (14). In order 
to differentiate LTP from residual tumor, it is necessary to 
have at least one contrast-enhanced follow-up study after 
ablation documenting adequate ablation and an absence of 
viable tissue in the target tumor by imaging criteria. Low 
LTP rates are desirable given the relationship between local 
disease control and disease-free survival, which is thought 
to ultimately influence OS (15).
Tumor size and ablation margins
Several factors have been described to be associated with 
local outcomes of ablation (16). Among the most relevant 
factors, tumor size and the minimal ablation margins are 
the two most widely recognized in several published series 
(16-20). 
The impact of tumor size—normally defined as the 
maximum longitudinal diameter in the uni-dimensional 
axial plane—on ablation outcomes has been extensively 
investigated. The literature supports the evidence that the 
smaller the lesion is, the most favorable the local outcome 
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will be. According to Veltri et al. (17), complete ablation was 
achieved in 66.7% of CLM <3 cm vs. 33.3% of CLM >3 cm 
(P<0.0001). More recently, these findings were confirmed 
by other investigators (18-22). Although 3 cm is the most 
commonly utilized tumor size cut-off for image-guided 
ablation eligibility in several institutions, the largest tumor 
size amenable to be effectively treated with thermal ablation 
is still a matter of debate. Indeed, image-guided ablation of 
CLM up to 5 cm can be acceptable in selected cases (20), 
and effective local tumor control rates can be achieved with 
adequate procedure planning and monitoring (23). 
Ablation margins are another critical factor affecting 
ablation outcomes. Several studies have demonstrated the 
importance of achieving minimal ablation margins that 
extend beyond the tumor in a three-dimensional plane 
at least 5 mm. According to Wang et al. (19), 2-year local 
tumor progression free survival (LTPFS) rates for ablated 
CLM with minimal ablation margins of 0, 1–5, 6–10, and 
11–15 mm were 26%, 46%, 74%, and 80%, respectively 
(P<0.011). In a recent report by Shady et al., CLM treated 
with minimal ablation margins >10 mm had no recurrence in 
a series including 110 patients (24). Thus, minimal ablation 
margin of >10 mm in all planes is considered with strong 
consensus as the optimal technical goal by an expert meeting 
position paper (16). Despite its criticality, achieving minimal 
ablation margins >10 mm is relatively difficult, as shown 
by some reports in the literature. Shady et al. reported 
ablation margins >10 mm were successfully obtained in only 
12% (21/174) of their historical series (18), while a two-
institution retrospective study showed that 28% (60/218) 
of the ablated CLM had ablation margins >10 mm (25). 
Nevertheless, it should be mentioned that these two published 
studies (18,25) consisted of retrospective patient series that 
pre-dated the most current evidence in regards optimal results 
associated with minimal ablation margins >10 mm.
RAS mutation and thermal ablation
Mutations in the RAS family of proto-oncogenes (KRAS, 
NRAS, HRAS) are present in 30–45% of the patients with 
colorectal cancers (8). These mutations cause a constitutive 
activation of the MAPK pathway, leading to resistance to 
treatment with EGFR antibodies. RAS mutations are the 
most well-recognized and relevant prognostic biomarker 
among patients undergoing CLM resection (26). More 
recently, published data also suggests an equivalent role in 
the image-guided ablation setting, as discussed below and 
summarized in Table 1.
In 2017, Odisio et al. showed that mutant RAS patients 
(both NRAS and KRAS) had shorter 3-year LTPFS 
Table 1 Published studies on RAS mutational status and image guided ablation of colorectal liver metastases
Authors/year Type of study
Number of 
patients/
lesions
Mean  
lesion 
size (cm)
RAS evaluation 
3 years  
LTPFS rate  
(RAS mut vs. 
RAS wt)
Other findings
Odisio et al. 
2017 (10)
Retrospective 92/137 1.6  KRAS codons 12,13, 61 and 146 
and NRAS codons 12, 13, 61 
35% vs.71%  Minimum ablation margin of  
less than 5 mm was found as 
negative predictors of local 
tumor progression-free survival
Calandri et al. 
2018* (25)
Two institutions/
retrospective
136/218 1.7 KRAS codons 12,13 in all patients, 
KRAS codons 59, 61, 117 and 146 
and NRAS codons 12, 13, 18, 59, 61, 
117 and 146 in the majority of them
35% vs.77% Minimal ablation margins >10 
mm and RAS status interact as 
independent predictors of LTPFS 
following CLM ablation 
Shady et al. 
2017 (27)
Retrospective 97/148 1.9 K-RAS (exon 2) 37% vs. 57% KRAS mutation was a  
significant predictor of new liver 
metastases (P=0.037) and  
peritoneal metastases (P=0.015) 
Jiang et al. 
2019 (28)
Retrospective 76/154 NA K-RAS (codons 12 and 13)  36.2% vs. 
11.1%**
m-CS (P=0.033) was an  
independent prognostic factor 
for LTP
*, overlapping series with Odisio 2017; **, LTP rates. RAS, rat sarcoma viral oncogene; LTPFS, local tumor progression free survival; CLM, 
colorectal liver metastases; m-CS, modified clinical score; LTP, local tumor progression.
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following liver ablation compared to wild-type RAS patients 
(35% versus 71% respectively; P=0.001) (10). In this same 
study, the authors also showed that among all the ablated 
CLM that presented with LTP, patients with mutant RAS 
recurred earlier and in smaller tumors when compared with 
those in wild-type RAS patients. In the same year, Shady 
et al. also showed mutant RAS as a significant predictor of 
LTP after CLM ablation with margins of 1–5 mm (P=0.018), 
with an LTP rate of 80% versus 41% for wild-type (27). 
The findings of these two seminal papers have been also 
confirmed by a recent paper, which found lower LTP rates 
in wild-type RAS patients (9.8%) when compared with 
mutant RAS patients (27.8%, P=0.004) (28). 
The relationship between RAS mutational status and 
minimal ablation margins has also been investigated 
(25,27). Calandri et al. (25) performed a two-institutional 
retrospective analysis of 136 patients submitted to CLM 
ablation. The authors demonstrated that 3-year LTPFS was 
significantly better among wild-type RAS tumors compared 
with mutant RAS tumors, irrespective of the minimal ablation 
margins achieved (≤10 mm ablation margins: 29% mutant 
RAS vs. 70% wild-type RAS, P<0.001; >10 mm ablation 
margins: 48% mutant RAS vs. 94% wild-type RAS, P=0.006). 
Based on their analysis, achieving minimal ablation margins 
>10 mm in mutant RAS tumors would provide similar 3-years 
LTPFS as achieving ≤10 mm ablation margins in wild-
type RAS tumors (P=0.36). In the previously mentioned 
series published by Shady et al. (27), the authors identified 
KRAS mutation as a significant independent predictor of 
LTP following RF ablation of CLM with minimal ablation 
margins of 1–5 mm (P=0.018). The authors also showed that 
mutant RAS tumors carried a risk of progression of 15.6-fold 
higher when compared with wild-type RAS tumors ablated 
with ablation margins of ≥6 mm. Therefore, the authors 
suggested that minimal ablation margins of ≥6 mm should 
be absolutely required (27), especially for mutant-type RAS 
tumors, and proposed minimal ablation margins of ≥10 mm 
as the treatment endpoint to offer the best possible local 
tumor control (25,27). 
Discussion
Ablative and surgical techniques and RAS: similarities and 
differences
Surgical data regarding CLM management have shown 
the role of RAS mutational status as both a prognostic 
factor of OS and as predictor of recurrence following 
surgery (9). Proposed strategies in the surgical literature 
for improving the outcomes of CLM resection according 
to the mutational RAS status are (I) the identification of 
specific predictive factors (in the mutant RAS patients); (II) 
a better understanding of the minimal resection margins 
required. Passot et al. (29), stratified mutant RAS patients 
who underwent surgery according to node-positivity of the 
primary tumor, CLM size >3 cm, and more than 7 cycles 
of preoperative chemotherapy, showing different OS in the 
subgroup analyses and proposed a pre-procedural scoring 
system.
Brudvik et al. demonstrated in a retrospective series 
that RAS mutations were associated with positive margins 
in patients undergoing resection of CLM, underlying a 
more infiltrative tumor behavior (30). Likewise, as for 
resection of tumors in proximity to vessels, if vascular R1 
can be considered as R0 parenchyma in case of wild-type 
RAS tumors, this is not acceptable for mutant RAS tumors 
(31,32). Very recently, these and other studies have led to 
a specific modified clinical score (m-CS) that includes the 
mutational RAS status, modified from the traditional risk-
score (t-cs); m-CS has been successfully validated, becoming 
a useful tool to predict survival after resection of CLM (33).
In the ablation literature, evidence concerning the 
role of RAS mutational status is more recent than the 
surgical literature. For more than a decade, publications 
concerning image-guided ablation have focused attention 
on its safety and efficacy, paying specific attention to the 
technical aspects. In recent years, the need to overcome 
the persistent relatively high LTP rates associated with 
ablation when compared with the recurrence rates reported 
in the surgical literature have led the interventional 
community to try to understand the role of tumor biology, 
highlighting that beyond technology, patient selection is of 
paramount importance (10). Despite this, presently, there 
is no consensus in regards to patient selection and ablation 
margins according of RAS mutational status (6,16). 
Although the RAS mutational status is not considered a 
contraindication to image-guided ablation, care should be 
exercised in the selection of the patients. Thus, considering 
the relationship between ablation margins, mutational 
status and LTPFS, we recommend that mutant RAS 
patients should be considered candidates for ablation only 
if adequate ablation margins can be planned and obtained. 
Specifically, a three-dimensional minimal ablation margins 
of ≥5 mm is always required in patients with mutant RAS, 
and, ideally, a minimal ablation margin of ≥10 mm should 
be highly desirable. Further refinements on imaging fusion 
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and biomechanical deformation methods should provide 
more accurate methods to assess minimal ablation margins 
intra-procedurally in order to improve the ability of 
achieving sufficient minimal ablation margins on a three-
dimensional plane.
The understanding of the relevance of tumor biology 
on local ablation outcomes may lead, in the near future, to 
unique tailored approaches for interventional procedures 
(especially in the case of mutant RAS patients) consisting 
of sequential treatments between systemic therapies (global 
treatment) and image-guided ablation (local treatment), in a 
so-called “glocal” approach (34).
RAS and other biomarkers in the OMD setting
Hellman proposed the term oligometastases for the 
first time in 1995 (35), suggesting that in some patients 
with a limited number of clinically detectable metastatic 
tumors, a limited tumor burden reflects a transitional state 
before widespread systemic disease. In this setting, local 
treatments of oligometastases would have the potential 
to yield improved systemic control (36). According to 
ESMO consensus guidelines, the oligometastatic condition 
is defined as the presence of metastases “at up to 2 or 
occasionally 3 sites and 5 or sometimes more lesions, 
predominantly visceral and occasionally lymphonodal.” 
This definition focuses on the global radiological tumor 
burden without including any tumor biology information. 
However, tumor biology deeply impacts the OS of all 
CRC patients including those who fit the OMD criteria, 
as shown by different aggressiveness and tumor growth 
kinetics (Figure 1). Furthermore, patients may be potentially 
considered in the OMD setting at different times during 
their disease history, even after selective selection of 
systemic therapies that may have changed the global 
genetic tumor profile and subsequently its aggressiveness 
(Figure 2). In the near future, efforts should be made 
to identify prognosticators for OMD. For instance, the 
use of circulating tumor DNA analysis in a longitudinal 
manner might prove to be a valuable surrogate of tumor 
aggressiveness in the OMD setting. In order to better select 
patients, a deeper knowledge of tumor genetics is required. 
Also, as recently understood and demonstrated, not all 
RAS mutations are equal (37,38), potentially with different 
impact on disease free survival and OS after local therapies. 
Finally, efforts are required to understand the interactions 
between different genes mutations, such as the case of co-
mutations of TP53 and RAS, which lead to a decreased OS 
after CLM resections (39). 
Conclusions
RAS mutat ional  s tatus  i s  emerging as  a  relevant 
prognosticator for LTP and OS after CLM image guided 
ablation. Available evidence suggests wider minimal 
ablations margins should be obtained in mutant RAS CLM 
patients in order to obtain improved LTPFS rates. Further 
studies are required to investigate specific interactions 
between RAS and other gene mutations, specific predictive 
factors of poor outcomes in the OMD setting in the mutant 
RAS CLM patient population and synergies between local 
Figure 1 Oligometastatic disease definition (based only on 
tumor burden) does not identify the best responders for local 
therapies. Red line represents aggressive tumors with rapid 
kinetic growth (RAS+, BRAF+, MSI+, Right colon origin, etc.). 
Blue line represents tumors with favorable prognosis and slow 
kinetics growth (RAS–, BRAF–, MSI– Left colon etc.). These less 
aggressive tumors can meet criteria as OMD for a longer period of 
time during their natural history. OMD, oligometastatic disease; 
RAS, rat sarcoma viral oncogene.
Figure 2 Oligometastatic disease definition (based only on tumor 
burden) does not reflect the potential differences of different OMD 
conditions during the natural history of the tumor and during local 
and systemic therapies. OMD, oligometastatic disease.
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and systemic therapies.
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